✦ LIBER ✦

P.1.016 - Fluvoxamine effective in preventing recurrence of major depression

✍ Scribed by J.L. Terra; F. Noël

Book ID: 119176666
Publisher: Elsevier Science
Year: 1996
Tongue: English
Weight: 156 KB
Volume: 6
Category: Article
ISSN: 0924-977X
DOI: 10.1016/0924-977x(96)83009-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-2-88 Comparison of fluvoxamine and flu

P-2-88 Comparison of fluvoxamine and fluoxetine in major depression

✍ M. Rapaport; E. Coccaro; Y. Sheline; P. Holland; T. Perse; L. Fabre 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 140 KB

P.2.a.016 Prevalence and clinical correl

P.2.a.016 Prevalence and clinical correlates of pain in patients with recurrent major depressive disorder

✍ S. Ahmed; A.F. Schatzberg; E.S. Friedman; A.J. Rothschild; M.H. Trivedi; D.L. Du 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Effectiveness of Fluvoxamine and Paroxet

Effectiveness of Fluvoxamine and Paroxetine in Major Depressives with Psychotic Features

✍ EMILIO SACCHETTI; GIOVANNI CONTE; LAURA GUARNERI; ALESANDRO CALZERONI; MARA BERT 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB 👁 1 views

Cost Effectiveness of Fluvoxamine in the

Cost Effectiveness of Fluvoxamine in the Treatment of Recurrent Depression in France

✍ Nuijten, Mark; Hadjadjeba, Lionel; Evans, Christopher; van den Berg, John 📂 Article 📅 1998 🏛 Springer International Publishing AG 🌐 English ⚖ 136 KB

P.1.a.016 CHL1 gene: a new promising ant

P.1.a.016 CHL1 gene: a new promising antidepressant response marker in major depression

✍ Fabbri, C.; Gurwitz, D.; Stingl, J.; Crisafulli, C.; Spina, E.; Kasper, S.; Zoha 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Controlled comparison of paroxetine and

Controlled comparison of paroxetine and fluvoxamine in major depression

✍ M. Ansseau; A. Gabriëls; J. Loyens; F. Bartholomé; J. L. Evrard; A. De Nayer; R. 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 681 KB

A multicentre study compared the antidepressant efficacy and the tolerance of two selective serotonin reuptake inhibitors, paroxetine (20-30 mg/d) and fluvoxamine (50-200 mg/d) in two parallel groups of respectively 56 and 64 patients with major depression, as defined by DSM-III-R criteria. The dura